Literature DB >> 18793553

Long-term (7-year-) treatment with lamivudine monotherapy in HBV-associated glomerulonephritis.

M Mesquita1, L Lasser, P Langlet.   

Abstract

Glomerulonephritis (GN) is an uncommon but well-described complication of chronic hepatitis B virus (HBV) infection. HBV-related membranous nephropathy (MN) may lead to renal failure in 1/3 of the patients and spontaneous remission is rare. There is no standard therapy for HBV-associated MN. We report a case of a 28-year-old man with HBV-associated MN due to pre-core HBV mutant with complete remission under an ongoing 7-year lamivudine monotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18793553     DOI: 10.5414/cnp70069

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  5 in total

1.  A case of anti-GBM glomerulonephritis superimposed on HBV-associated membranous nephropathy.

Authors:  Takeshi Yamamoto; Susumu Oseto; Natsuko Imakita; Masami Inada; Megumu Fukunaga
Journal:  CEN Case Rep       Date:  2013-04-13

2.  Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.

Authors:  Carla S Coffin; Scott K Fung; Mang M Ma
Journal:  Can J Gastroenterol       Date:  2012-12       Impact factor: 3.522

3.  Steroid treatment in patients with membranous nephropathy and hepatitis B virus surface antigenemia: a report of two cases.

Authors:  Tetsu Akimoto; Toshiya Otake; Akira Tanaka; Hideaki Takahashi; Toshihiko Higashizawa; Makoto Inoue; Katsuhiko Nishino; Osamu Saito; Norio Isoda; Shigeaki Muto; Kentaro Sugano; Eiji Kusano
Journal:  Clin Exp Nephrol       Date:  2010-12-18       Impact factor: 2.801

4.  Hepatitis B virus X protein up-regulates tumor necrosis factor-α expression in cultured mesangial cells via ERKs and NF-κB pathways.

Authors:  Hong-Zhu Lu; Jian-Hua Zhou
Journal:  Asian Pac J Trop Biomed       Date:  2013-03

5.  Effectiveness of telbivudine antiviral treatment in patients with hepatitis B virus-associated glomerulonephritis: A 104-week pilot study.

Authors:  Zhaoping Yan; Bing Qiao; Haifeng Zhang; Yanling Wang; Wei Gou
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.